BioCentury | Feb 24, 2018
Strategy

Patients as pawns

...program for Fycompa. As a result, German authorities used the lowest cost comparators lamotrigine and topiramate...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc. ’s Qsiva phentermine/topiramate...
BioCentury | Jun 23, 2017
Clinical News

Novo’s semaglutide shows obesity benefit in Phase II trial

...side effects were the most common adverse events. Among obesity drugs launched over 2012-14, Qsymia phentermine/topiramate...
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

...largest obesity product was Vivus Inc. ’s Qsymia , a low-dose combination of phentermine and topiramate...
BioCentury | Sep 19, 2016
Product Development

Getting ahead of headache

...on the frequency and severity of headaches. Standard of care for both indications includes generic topiramate...
...that are difficult to tolerate in a chronic setting, such as weight gain or sedation. Topiramate...
...and III trials were allowed to remain on stable background therapy with preventive agents like topiramate...
BioCentury | Sep 5, 2016
Clinical News

Trokendi XR topiramate regulatory update

...FDA granted final approval to an sNDA from Supernus for Trokendi XR topiramate as monotherapy treatment...
...in adults. The company expects to receive final approval when pediatric exclusivity for immediate-release Trokendi topiramate...
...seizures or with seizures associated with Lennox-Gastaut syndrome. The drug is an extended-release formulation of topiramate...
BioCentury | Jun 27, 2016
Clinical News

Trokendi XR topiramate regulatory update

...Supernus said FDA asked the company to resubmit its proposed label for Trokendi XR topiramate to...
...PDUFA date was in 2Q16. The extended-release formulation of topiramate is approved to treat epilepsy. Topiramate...
...receptor antagonist and carbonic anhydrase inhibitor. Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Product: Trokendi XR topiramate...
BioCentury | Mar 7, 2016
Analyst Picks & Changes

Analyst picks & changes

...to $1 from $4. He said Vivus' financial position prevents it from commercially supporting Qsymia phentermine/topiramate...
BioCentury | Nov 9, 2015
Company News

Supernus, Endo deal

...Supernus granted Endo’s Par Pharmaceutical company rights to sell the generic version of Trokendi XR topiramate...
...submitted an ANDA for approval of a generic version of Supernus’ extended release formulation of topiramate...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...it will further reduce the number of contractual sales representatives for its obesity drug Qsymia phentermine/topiramate...
Items per page:
1 - 10 of 475